Topic
Pharmaceuticals
1,006 published works
Big Molecule Watch
Amneal and Kashiv File IPR Petition on Omalizumab Patent
By Timothy Beavers|Josh Eibelman
On May 26, 2026, Amneal Pharmaceuticals, Inc. and Kashiv Biosciences petitioned for inter partes review (IPR2026-00260) of all claims of U.S. Patent No. 12,030,959 (“the ’959 patent”), assigned to Novartis…
Big Molecule Watch
Eli Lilly Expands Vaccine Portfolio by Acquiring Three Developers
On May 26, 2026, Eli Lilly announced that it had entered into agreements to acquire LimmaTech Biologics AG, Curevo Inc., and Vaccine Company, Inc. as part of its expanded research…
Big Molecule Watch
FDA Approves First Interchangeable Biosimilars to Simponi and Simponi Aria; Janssen Seeks a Preliminary Injunction to Block Their Launch
By Sarah Adam
On May 15, 2026, the U.S. Food and Drug Administration (“FDA”) approved Accord BioPharma’s IMMGOLIS (golimumab-sldi) as an interchangeable biosimilar to Janssen’s SIMPONI® (golimumab), and IMMGOLIS INTRI (golimumab-sldi) as an…
GoodLifeSci
EU Pharma Package: Compromise Text Published – Best Efforts Required (Part 2)
By Maarten Meulenbelt, Josefine Sommer, Dr. Chris Boyle, Anne Robert, Alix Vermulst, Belinda Baum, Anna-Shari Melin
After a 10-year process, the compromise text of the new EU General Pharmaceutical Legislation (GPL or Pharma Package) has been published and will soon become law. This blog post discusses…
IP IQ
A Bitter pH-ill to Swallow: Federal Circuit Affirms Mylan’s Win Over Actelion’s Epoprostenol Drug Patents
Last week in Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., the Federal Circuit delivered generic drug maker Mylan Pharmaceuticals Inc. with a notable victory when it affirmed the district court’s judgment…
Drug Injury Watch
Tavneos Warnings For VBDS Liver Side Effect Increased In April 2026
By Tom Lamb
Tavneos Drug Label Change By Amgen Just 2 Days After Tavneos Drug Recall Statement By FDA (Posted by Tom Lamb at Drug Injury Watch) The Tavneos drug safety issue has an interesting new…
Environment, Land & Resources
EPA’s Draft Sixth Contaminant Candidate List Targets Microplastics and Pharmaceuticals in Drinking Water
EPA’s decision, paired with a newly unveiled research program from the Department of Health and Human Services, increases scrutiny on these emerging contaminants. By Julia A. Hatcher, Tom Lee, Hunter…
India Corporate Law
Beyond the Advisory – The Legal Framework Governing GLP-1 Drug Advertising (Part 2)
By Biplab Lenin Vineet Unnikrishnan, Sonu Bhasi, Kashish Gupta
Summary: This article examines the reach of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, through the lens of key judicial pronouncements – from the Supreme Court’s ruling in…
The IPKat
Pharma & Biotech Patent Litigation in Europe conference returns with IPKat readers’ discount
If, like this Kat, you love all things pharma, biotech and patents, then the Pharma & Biotech Patent Litigation in Europe conference is for you. The IPKat is also happy to report…
Health Law Diagnosis
How PBM Reform Suddenly Got Rolling
By Ivy Miller
Below is an excerpt of an article published in the Massachusetts Bar Association's Section Review. Recent months have seen a significant shift in how pharmacy benefit managers (PBMs) are regulated…